Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a prospective, multicenter, open-label, single-arm study in participants with metastatic pancreatic adenocarcinoma who have not received any prior systemic anti-tumor therapy for advanced disease. To evaluate the efficacy and safety of albumin-bound paclitaxel (II) combined with gemcitabine for first-line treatment of metastatic pancreatic cancer.
Epistemonikos ID: ec85c052dbb280657267bf99ac3b83d0ab218844
First added on: Sep 22, 2026